Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2019 Filed Jul 20, 2019 01:38 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,361 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001567619-19-015051 · doc1.xml · derivative · entry 2 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,361 Underlying: Common Stock · 10,361 shares Expires 2029-07-17 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:38 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
GrantCommon Stock | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015051 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,748 F1 · shares: This acquisition of 3,098 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,098 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:36 UTC |
Boucher Brent J.SVP and GM of Oncology
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,790 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001567619-19-015049 · doc1.xml · derivative · entry 2 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,790 Underlying: Common Stock · 10,790 shares Expires 2029-07-17 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:36 UTC |
Boucher Brent J.SVP and GM of Oncology
|
GrantCommon Stock | 3,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015049 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,769 F1 · shares: This acquisition of 3,226 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,226 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:34 UTC |
Helsel DaveSVP Global Operations and R&D
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,615 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001567619-19-015047 · doc1.xml · derivative · entry 2 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,615 Underlying: Common Stock · 11,615 shares Expires 2029-07-17 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:34 UTC |
Helsel DaveSVP Global Operations and R&D
|
GrantCommon Stock | 3,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015047 · doc1.xml · nonDerivative · entry 1 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,563 F1 · shares: This acquisition of 3,473 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,473 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:32 UTC |
Trowbridge Stephen ASVP and General Counsel
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,975 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001567619-19-015044 · doc1.xml · derivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,975 Underlying: Common Stock · 13,975 shares Expires 2029-07-17 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:32 UTC |
Trowbridge Stephen ASVP and General Counsel
|
GrantCommon Stock | 4,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015044 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,413 F1 · shares: This acquisition of 4,178 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,178 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:28 UTC |
Greiner MichaelEVP and CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,621 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001567619-19-015041 · doc1.xml · derivative · entry 2 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,621 Underlying: Common Stock · 25,621 shares Expires 2029-07-17 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:28 UTC |
Greiner MichaelEVP and CFO
|
GrantCommon Stock | 7,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015041 · doc1.xml · nonDerivative · entry 1 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,391 F1 · shares: This acquisition of 7,660 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,660 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:12 UTC |
Gould Kevin JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $11.92 | $0.00 |
DisclosureSEC source: 0001567619-19-014983 · doc1.xml · derivative · entry 5 Gould Kevin J · CIK 0001504093 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2020-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/06/2014, 08/06/2015, 08/06/2016 and 08/06/2017, respectively. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:12 UTC |
Gould Kevin JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,650 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001567619-19-014983 · doc1.xml · derivative · entry 4 Gould Kevin J · CIK 0001504093 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,650 shares Expires 2019-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/07/2013, 08/07/2014, 08/07/2015 and 08/07/2016, respectively. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:12 UTC |
Gould Kevin JDirector
|
SaleCommon Stock | 13,650 | $21.45 | $292,792.50 |
DisclosureSEC source: 0001567619-19-014983 · doc1.xml · nonDerivative · entry 3 Gould Kevin J · CIK 0001504093 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,124 Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:12 UTC |
Gould Kevin JDirector
|
Exercise / conversionCommon Stock | 7,000 | $11.92 | $83,440.00 |
DisclosureSEC source: 0001567619-19-014983 · doc1.xml · nonDerivative · entry 2 Gould Kevin J · CIK 0001504093 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:12 UTC |
Gould Kevin JDirector
|
Exercise / conversionCommon Stock | 6,650 | $10.68 | $71,022.00 |
DisclosureSEC source: 0001567619-19-014983 · doc1.xml · nonDerivative · entry 1 Gould Kevin J · CIK 0001504093 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2019 Filed Jul 18, 2019 16:15 UTC |
GOLD JEFFREYDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,650 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001567619-19-014985 · doc1.xml · derivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,650 shares Expires 2019-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/07/2013, 08/07/2014, 08/07/2015 and 08/07/2016, respectively. Read SEC document |
| July 12, 2019 Filed Jul 18, 2019 16:15 UTC |
GOLD JEFFREYDirector
|
Tax withholdingCommon Stock | 3,276 | $21.68 | $71,023.68 |
DisclosureSEC source: 0001567619-19-014985 · doc1.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,583 Read SEC document |
| July 12, 2019 Filed Jul 18, 2019 16:15 UTC |
GOLD JEFFREYDirector
|
Exercise / conversionCommon Stock | 6,650 | $10.68 | $71,022.00 |
DisclosureSEC source: 0001567619-19-014985 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 01:59 UTC |
Clemmer James CDirector · President and CEO
|
Exercise / conversionPerformance Right · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017316 · doc1.xml · derivative · entry 3 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On April 1, 2016, the reporting person received a target grant of 250,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 200,000 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On April 1, 2016, the reporting person received a target grant of 250,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 200,000 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On April 1, 2016, the reporting person received a target grant of 250,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 200,000 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 01:59 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 96,140 | $21.68 | $2,084,315.20 |
DisclosureSEC source: 0001567619-19-017316 · doc1.xml · nonDerivative · entry 2 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,418 F2 · shares: The exempt disposition of 96,140 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on April 1, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 01:59 UTC |
Clemmer James CDirector · President and CEO
|
Exercise / conversionCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017316 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 200,000 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on April 1, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 02:00 UTC |
Simpson Robert ArthurSVP/GM, Global Vascular
|
Exercise / conversionPerformance Right · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017318 · doc1.xml · derivative · entry 3 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On January 31, 2017, the reporting person received a target grant of 30,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 15,600 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 02:00 UTC |
Simpson Robert ArthurSVP/GM, Global Vascular
|
Tax withholdingCommon Stock | 5,158 | $21.68 | $111,825.44 |
DisclosureSEC source: 0001567619-19-017318 · doc1.xml · nonDerivative · entry 2 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,883 F2 · shares: The exempt disposition of 5,158 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on January 31, 2017. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 02:00 UTC |
Simpson Robert ArthurSVP/GM, Global Vascular
|
Exercise / conversionCommon Stock | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017318 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 15,600 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on January 31, 2017. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 01:58 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Exercise / conversionPerformance right · Derivative | 6,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017315 · doc1.xml · derivative · entry 3 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,103 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On July 27, 2016, the reporting person received a target grant of 6,103 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,174 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On July 27, 2016, the reporting person received a target grant of 6,103 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,174 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On July 27, 2016, the reporting person received a target grant of 6,103 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,174 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 01:58 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 1,050 | $21.68 | $22,764.00 |
DisclosureSEC source: 0001567619-19-017315 · doc1.xml · nonDerivative · entry 2 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,052 F2 · shares: The exempt disposition of 1,050 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 27, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 01:58 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Exercise / conversionCommon Stock | 3,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017315 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 3,174 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 27, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 10:14 UTC |
Trowbridge Stephen ASVP and General Counsel
|
Exercise / conversionPerformance Right · Derivative | 6,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017322 · doc1.xml · derivative · entry 3 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,894 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On July 27, 2016, the reporting person received a target grant of 6,894 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,585 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On July 27, 2016, the reporting person received a target grant of 6,894 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,585 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On July 27, 2016, the reporting person received a target grant of 6,894 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,585 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 10:14 UTC |
Trowbridge Stephen ASVP and General Counsel
|
Tax withholdingCommon Stock | 1,185 | $21.68 | $25,690.80 |
DisclosureSEC source: 0001567619-19-017322 · doc1.xml · nonDerivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,123 F2 · shares: The exempt disposition of 1,185 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 27, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 10:14 UTC |
Trowbridge Stephen ASVP and General Counsel
|
Exercise / conversionCommon Stock | 3,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017322 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 3,585 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 27, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 10:08 UTC |
Greiner MichaelEVP and CFO
|
Exercise / conversionPerformance Right · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017320 · doc1.xml · derivative · entry 3 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On August 18, 2016, the reporting person received a target grant of 20,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 10,400 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.exercise_date: On August 18, 2016, the reporting person received a target grant of 20,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 10,400 shares of Common Stock were issued to the reporting person under this grant. F3 · derivative.expiration_date: On August 18, 2016, the reporting person received a target grant of 20,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 10,400 shares of Common Stock were issued to the reporting person under this grant. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 10:08 UTC |
Greiner MichaelEVP and CFO
|
Tax withholdingCommon Stock | 3,440 | $21.68 | $74,579.20 |
DisclosureSEC source: 0001567619-19-017320 · doc1.xml · nonDerivative · entry 2 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,264 F2 · shares: The exempt disposition of 3,440 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on August 18, 2016. Read SEC document |
| July 12, 2019 Filed Aug 20, 2019 10:08 UTC |
Greiner MichaelEVP and CFO
|
Exercise / conversionCommon Stock | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-017320 · doc1.xml · nonDerivative · entry 1 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This acquisition of 10,400 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on August 18, 2016. Read SEC document |
| June 28, 2019 Filed Jul 16, 2019 16:26 UTC Amendment |
Meteny Dennis SDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,650 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001567619-19-014855 · doc1.xml · derivative · entry 3 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,650 shares Expires 2019-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/07/2013, 08/07/2014, 8/07/2015 and 08/07/2016, respectively. Read SEC document |
| June 28, 2019 Filed Jul 16, 2019 16:26 UTC Amendment |
Meteny Dennis SDirector
|
Tax withholdingCommon Stock | 3,607 | $19.69 | $71,021.83 |
DisclosureSEC source: 0001567619-19-014855 · doc1.xml · nonDerivative · entry 2 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,021 F1 · security: This Amended Form 4 is being filed to correct inaccuracies in the Form 4 filed on July 3, 2019 with respect to the transaction date, sales price and number of shares sold following exercise of the option reported in Table II. Read SEC document |
| June 28, 2019 Filed Jul 16, 2019 16:26 UTC Amendment |
Meteny Dennis SDirector
|
Exercise / conversionCommon Stock | 6,650 | $10.68 | $71,022.00 |
DisclosureSEC source: 0001567619-19-014855 · doc1.xml · nonDerivative · entry 1 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Amended Form 4 is being filed to correct inaccuracies in the Form 4 filed on July 3, 2019 with respect to the transaction date, sales price and number of shares sold following exercise of the option reported in Table II. Read SEC document |
| May 31, 2019 Filed Jul 3, 2019 17:58 UTC |
Meteny Dennis SDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,650 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001567619-19-014436 · doc1.xml · derivative · entry 3 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,650 shares Expires 2019-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/07/2013, 08/07/2014, 8/07/2015 and 08/07/2016, respectively. Read SEC document |
| May 31, 2019 Filed Jul 3, 2019 17:58 UTC |
Meteny Dennis SDirector
|
Tax withholdingCommon Stock | 3,780 | $18.79 | $71,026.20 |
DisclosureSEC source: 0001567619-19-014436 · doc1.xml · nonDerivative · entry 2 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,848 Read SEC document |
| May 31, 2019 Filed Jul 3, 2019 17:58 UTC |
Meteny Dennis SDirector
|
Exercise / conversionCommon Stock | 6,650 | $10.68 | $71,022.00 |
DisclosureSEC source: 0001567619-19-014436 · doc1.xml · nonDerivative · entry 1 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 16:53 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 858 | $19.15 | $16,430.70 |
DisclosureSEC source: 0001567619-19-012041 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,650 F1 · shares: The exempt disposition of 858 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:21 UTC |
Trowbridge Stephen ASVP and General Counsel
|
Tax withholdingCommon Stock | 1,319 | $20.64 | $27,224.16 |
DisclosureSEC source: 0001567619-19-009204 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,235 F1 · shares: The exempt disposition of 1,319 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 24, 2015. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 20:09 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 4,232 | $22.95 | $97,124.40 |
DisclosureSEC source: 0001567619-19-008523 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,476 F1 · shares: The exempt disposition of 4,232 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 4, 2016. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:14 UTC |
Boucher Brent J.SVP and GM of Oncology
|
Tax withholdingCommon Stock | 490 | $22.90 | $11,221.00 |
DisclosureSEC source: 0001567619-19-004544 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,543 F1 · shares: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 12, 2018. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 21:24 UTC |
Simpson Robert ArthurSVP/GM, Global Vascular
|
Tax withholdingCommon Stock | 981 | $21.10 | $20,699.10 |
DisclosureSEC source: 0001567619-19-002168 · doc1.xml · nonDerivative · entry 1 Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,142 F1 · shares: The exempt disposition of 981 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on January 31, 2017. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 21:06 UTC |
Greiner MichaelEVP and CFO
|
SaleCommon Stock | 1,939 | $21.53 | $41,746.67 |
DisclosureSEC source: 0001567619-18-005419 · doc1.xml · nonDerivative · entry 1 Greiner Michael · CIK 0001520392 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,731 Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 22:56 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 1,752 | $21.42 | $37,527.84 |
DisclosureSEC source: 0001140361-18-034274 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,708 F1 · shares: The exempt disposition of 1,752 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 22:57 UTC |
Trowbridge Stephen ASVP and General Counsel
|
Tax withholdingCommon Stock | 285 | $21.42 | $6,104.70 |
DisclosureSEC source: 0001140361-18-034277 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,554 F1 · shares: The exempt disposition of 285 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 22:53 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 252 | $21.42 | $5,397.84 |
DisclosureSEC source: 0001140361-18-034272 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,508 F1 · shares: The exempt disposition of 252 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| July 26, 2018 Filed Jul 27, 2018 23:58 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 1,826 | $21.88 | $39,952.88 |
DisclosureSEC source: 0001140361-18-033942 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,460 F1 · shares: The exempt disposition of 1,826 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
| July 26, 2018 Filed Jul 28, 2018 00:13 UTC |
Trowbridge Stephen ASVP and General Counsel
|
Tax withholdingCommon Stock | 306 | $21.88 | $6,695.28 |
DisclosureSEC source: 0001140361-18-033950 · doc1.xml · nonDerivative · entry 3 Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,839 F3 · shares: The exempt disposition of 306 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.